Making it in Manufacturing

ARTO Talent
  • 0.0 (0)
  • Careers
  • Weekly

97% of our listeners don't realise they aren't followed, please double check, thank you! Hosted by Thomas McMann, Making It In Manufacturing is ARTO's new in-person podcast series, spotlighting the leaders shaping the future of manufacturing, engineering and CDMOs in Life Sciences. Each episode dives into the careers, decisions, and defining moments of industry mainstays - revealing the stories and insights behind real-world impact within the life science manufacturing and CDMO space. If you're a leader in the space - or aspiring to be - this podcast is a must watch. The series is available on YouTube, Spotify, Apple Podcasts and all major platforms. Hosted on Acast. See acast.com/privacy for more information.

  1. 18h ago

    CPHI Milan 2026: From 500 Million To A Billion Units - Ankit Gupta

    95% of our viewers aren't subscribed. If you're watching and not yet subscribed, please subscribe to the channel so you don't miss future episodes. Register your interest for 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-arto A year ago, InstaPill was adding a new block to take its capacity in India to 500 million units. Now CEO Ankit Gupta plans a new greenfield site to double that to a billion, able to handle everything that is ODT. This week on Making It In Manufacturing, Harry Sloan caught up again with Ankit Gupta, CEO of InstaPill, at CPHI Milan 2026, where ARTO was the official podcast partner. In this episode, Ankit covers: (01:12) Why InstaPill is planning a new greenfield site in India, on about 18 acres of land, modular so capacity can grow with demand. (02:35) The move to a CDMO and B2B model, built on its two strengths: development and manufacturing. (03:55) What sets InstaPill apart: transparency and flexibility, with projects partners typically do in 9 to 10 months delivered in 3 to 6. (05:01) Where a US site fits: the bulk of its partners are in the US, and the plan stays on track for when partners need it. (06:22) What to ask him about next year: more visible partnerships and more products reaching the market. Watch the full episode to hear why Ankit wants partners to think of InstaPill as the company that can do everything that is possible on ODT. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent/ Spotify: https://open.spotify.com/show/1cSZVJ63yXJ3kqnVORyTbw Instagram: https://www.instagram.com/arto.talent TikTok: https://www.tiktok.com/@artotalent Apple Podcasts: https://podcasts.apple.com/gb/podcast/making-it-in-manufacturing/id1819731245 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@artotalent Ankit Gupta LinkedIn: https://www.linkedin.com/in/reachankit/ Harry Sloan LinkedIn: https://www.linkedin.com/in/harry-sloan-605620154/ Timestamps: 00:00 Introduction 01:12 Doubling to a billion units 02:35 From own products to CDMO partner 03:55 Transparency and flexibility 05:01 The plan for the US 06:22 What to watch for next year #MakingItInManufacturing #ARTOTalent #CPHI #CPHIMilan #ODT #CDMO #DrugDelivery #PharmaManufacturing Hosted on Acast. See acast.com/privacy for more information.

    CPHI Milan 2026: From 500 Million To A Billion Units - Ankit Gupta

  2. 4d ago

    CPHI Milan 2026: Taking Manufacturing Out Of The Dark Ages - Sheena Dempsey

    Drug discovery and clinical development have all benefited from the COVID era and the AI era, but for Sheena Dempsey, manufacturing is still stuck somewhat in the dark ages. As President and CEO of CAI, she wants to drive automation and acceleration that get medicines into the hands of patients faster. This week on Making It In Manufacturing, Elliot Payne sat down with Sheena Dempsey, President and CEO of CAI, the global consultancy for commissioning and qualification and operational readiness, at CPHI Milan 2026, where ARTO was the official podcast partner. In this episode, Sheena covers: (00:57) What CAI does: commissioning and qualification, operational readiness and operational excellence for most of the top pharmaceutical companies, with about 750 people across North America, Europe and APAC. (02:06) The new partnership with JLL Partners, and her three to five year plan to grow CAI, organically and inorganically, in footprint and in services. (03:13) What drew her to CAI after building life sciences practices in professional services, and why she calls herself a global misfit. (04:44) Getting experienced people and Gen Z and Gen Alpha digital natives working well together: the goals are the same, and it takes leadership, change management and training on both sides. (06:58) Why paper in manufacturing plants is unacceptable today, and why digitisation lends itself to compliance and stops knowledge being lost. (07:43) What CAI looks for in new people, and managing talent as a portfolio, from trade schools and internships to graduates. (10:03) Why CAI is building its own trade school pipeline for aseptic manufacturing, where the demand for talent is enormous. (12:06) What success in 2027 looks like: the right balance of skills, global teams built around a customer's need, and the excitement of a plant's first batch. (13:31) The one thing she would remove from pharma manufacturing: its deeply held resistance to change. (14:23) Why she is optimistic: pockets of real innovation at particular sites, led by site heads and change agents. Watch the full episode to hear why Sheena believes the inflection point manufacturing needs is already in play. Register your interest for CPHI Frankfurt 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-arto Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent/ Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent TikTok: https://www.tiktok.com/@artotalent Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@artotalent Sheena Dempsey LinkedIn: https://www.linkedin.com/in/sheena-dempsey-b693575/ Elliot Payne LinkedIn: https://www.linkedin.com/in/elliot-payne-2a4a917a/ Timestamps: 00:00 Introduction 00:57 What CAI does 02:06 The JLL Partners partnership 03:13 Why Sheena chose CAI 04:44 Bringing generations together 06:58 Taking paper out of manufacturing 07:43 What CAI looks for in talent 10:03 Building a trade school pipeline 12:06 What success looks like in 2027 13:31 One thing to remove from the industry 14:23 Reasons for optimism #MakingItInManufacturing #ARTOTalent #CPHI #CPHIMilan #Commissioning #Qualification #Digitalisation #PharmaManufacturing Hosted on Acast. See acast.com/privacy for more information.

    CPHI Milan 2026: Taking Manufacturing Out Of The Dark Ages - Sheena Dempsey

  3. 5d ago

    The CEO’s Weekly Challenge: Capacity or Indication | CPHI Milan 2026 CEO Panel

    This week on Making It In Manufacturing, we’re bringing you our CEO panel from CPHI Milan 2026. ARTO Co-Founder and CEO Elliot Payne sat down with three CDMO CEOs: Dr Hanns-Christian Mahler of ten23 health, Dr Adriana Kiędzierska-Mencfeld of Rezon Bio and Philippe Clavel of Curapath, to ask how they weigh capacity risk against indication risk. In this panel: - Why ordering a sterile filling machine today can mean five to seven years before the first GMP fill - How Rezon Bio builds capacity in stages, and why the team is the biggest asset and the biggest risk - How Curapath helped an ALS customer go from 16 polymer drug conjugates to four on the way to phase two - Fixed platforms with flexible indications, and when one facility can serve many - The latest build, buy or partner calls each CEO has made - Data or instinct: how they decide where to invest next - The one thing each of them would remove from pharma manufacturing Be sure to watch to the end for the quickfire round. Register your interest for CPHI Frankfurt 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-arto 🤝 Thank you to CPHI and Informa Markets for having us as official podcast partners at CPHI Milan 2026. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent TikTok: https://www.tiktok.com/@artotalent Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ YouTube: https://www.youtube.com/@artotalent Making It In Manufacturing playlist: https://www.youtube.com/playlist?list=PL_xXnfiK8dI5gHJr13c23WSFNHYc4d6_4 The panel : Hanns-Christian Mahler, CEO, ten23 health: https://www.linkedin.com/in/hanns-christian-mahler/ Adriana Kiędzierska-Mencfeld, CEO, Rezon Bio: https://www.linkedin.com/in/dr-adriana-kiedzierska-mencfeld/ Philippe Clavel, CEO, Curapath: https://www.linkedin.com/in/philippe-clavel-cdmo-gxapis/ Moderated by Elliot Payne, Co-Founder and CEO, ARTO: https://www.linkedin.com/in/elliot-payne-2a4a917a/ Timestamps: 0:00 Intro 0:15 Welcome to the CEO’s Weekly Challenge 0:50 How do you weigh capacity risk against indication risk? 6:50 ten23 health: the science, not the disease 9:06 Do biosimilars take indication risk out? 10:56 Curapath’s ALS customer: from 16 conjugates to four 12:28 Fixed platform, flexible indications 15:31 Fast, flexible capacity: real or a marketing ploy? 23:29 Biosimilars: flexibility or analytical rigour? 26:03 Can one facility serve many indications and be best in class? 28:29 The latest build, buy or partner call 33:35 Data or instinct? 40:34 Quickfire: one thing to remove from pharma manufacturing #MakingItInManufacturing #ARTOTalent #CPHIMilan #CPHI2026 #CDMO #PharmaManufacturing #Biotech #LifeSciences #Biosimilars #DrugDelivery Hosted on Acast. See acast.com/privacy for more information.

    The CEO’s Weekly Challenge: Capacity or Indication | CPHI Milan 2026 CEO Panel

  4. 6d ago

    CPHI Milan 2026 Newsbeat: 53Biologics Takes Fill And Finish Fully In House - Javier Santos

    53Biologics is adding new lyophilisation equipment and an isolator to its facilities, completing its fill and finish capabilities so the company is fully end to end. That means the small batches first clinical trials need can stay under one roof. On Newsbeat, live at CPHI Milan 2026, Ruby Collier spoke to Javier Santos, Business Developer at 53Biologics, about the company's new in-house lyophilisation and what it means for customers' clinical programmes. In this episode, Javier covers: (00:33) 53Biologics' new lyophilisation equipment and isolator, which complete its fill and finish capabilities and make the company end to end, in line with its philosophy. (01:05) Why the small batches needed for first clinical trials are so hard to place with outside fill and finish suppliers, and how bringing the work in house removes that bottleneck, especially in phase one. (02:14) How keeping every step with one partner makes customers' projects quicker and more efficient, with no extra contracts and no separate providers' timelines to manage. (03:13) What his conversations at CPHI have confirmed: clients across many projects are asking for the same small batches, so the capability needs to be in place. Watch the full episode to hear why Javier sees having everything under one roof as the answer to the small-batch bottleneck. Register your interest for CPHI Frankfurt 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-arto Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent/ Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent TikTok: https://www.tiktok.com/@artotalent Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@artotalent Javier Santos LinkedIn: https://www.linkedin.com/in/javier-santos-aberturas-96b7a45a/ Ruby Collier LinkedIn: https://www.linkedin.com/in/ruby-collier/ Timestamps: 00:00 Introduction 00:52 Why small clinical batches need in-house fill and finish 01:58 Simpler projects, everything in one place 02:58 What CPHI conversations have confirmed 03:52 Closing thoughts #Newsbeat #ARTOTalent #CPHI #CPHIMilan #FillAndFinish #Lyophilisation #Biologics #CDMO Hosted on Acast. See acast.com/privacy for more information.

    CPHI Milan 2026 Newsbeat: 53Biologics Takes Fill And Finish Fully In House - Javier Santos

  5. 6d ago

    "I Want Regulators To Say There's A Safer Alternative" | 4basebio's 10-Year Plan

    95% of our viewers aren't subscribed. If you're watching and not yet subscribed, please subscribe to the channel so you don't miss future episodes. This week on Making It In Manufacturing, Thomas McMann sat down with Dr Amy Walker, CEO of 4basebio. In this episode, Amy covers: • Why DNA has been made the same way for 50 years, and what changes when you take the bacteria out of the process entirely. • How 4basebio's enzymatic platform works, and why it cuts GMP grade DNA from a 6 to 9 month wait down to under 12 weeks. • What it was actually like joining as the company's first employee, when 4basebio was an empty building on an industrial estate outside Cambridge. • The funding headwinds of the last two years, what happens when a client loses their NIH funding overnight, and how they diversified the client base around it. • Why she believes synthetic DNA disrupting plasmid is a question of when rather than if, and what she wants regulators saying about it in ten years' time. Worth watching if you work anywhere near cell and gene therapy, mRNA, viral vectors or DNA supply. Even if plasmid isn't your day to day, it's a clear look at how an established manufacturing process gets displaced, and what it takes to get conservative buyers to switch. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent/ Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent TikTok: https://www.tiktok.com/@artotalent Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/channel/UCkoSWF_xqX4i9OIkX4pGaxQ Dr Amy Walker LinkedIn: https://www.linkedin.com/in/amy-walker-4a9785154/ Thomas McMann LinkedIn: https://www.linkedin.com/in/thomas-mcmann-05540a10b Timestamps: 00:00 Introduction 01:35 What 4basebio does 02:10 Operating as a CDMO 02:48 Why plasmid DNA hasn't changed in 50 years 04:09 The safety benefits of removing bacteria 04:49 Lowering the dose required 05:23 From 6 to 9 months down to under 12 weeks 05:36 Personalised cancer vaccines 05:53 Touchlight and why there is so little competition 06:25 How mRNA vaccines changed the conversation 07:36 TruePrime and opDNA explained 08:44 Clean rooms no bigger than a podcast booth 09:46 Why cell free is the real difference 10:48 Joining 4basebio as its first employee 12:01 Head of Discovery to COO to CEO 13:09 Balancing the science and the commercial 14:14 The funding headwinds of the last two years 15:37 GMP certification and getting into the clinic 17:00 Persuading big pharma to switch 17:47 The regulatory objection 19:54 The Genezen partnership 20:32 "There was nothing to see. It was an empty building" 23:31 The advantage of having worn every hat 24:41 Where the strongest growth is coming from 26:41 The case for vertical integration 28:46 Sustainability 29:44 Where 4basebio is in ten years 30:49 Quickfire questions #MakingItInManufacturing #ARTOTalent #4basebio #SyntheticDNA #PlasmidDNA #CellAndGeneTherapy #mRNA #ViralVectors #CDMO #Biomanufacturing Hosted on Acast. See acast.com/privacy for more information.

    "I Want Regulators To Say There's A Safer Alternative" | 4basebio's 10-Year Plan

  6. Oct 26

    CPHI Milan 2026 Newsbeat: Ensera Launches The Ensera Alliance Network - Darren Hieber

    Ensera has launched the Ensera Alliance Network at CPHI Milan 2026. It brings like-minded companies together across the value chain, from drug product manufacturing and fill finish to assembly, packaging and serialisation. On Newsbeat, live at CPHI Milan 2026, Ruby Collier spoke to Darren Hieber, VP Alliance Partnerships at Ensera, about the network and what it offers pharma companies. In this episode, Darren covers: (00:26) What the Ensera Alliance Network is: drug product CDMOs, equipment makers and platform auto-injector companies working together, with six groups in so far and plans to expand. (01:41) How the network brings well-respected specialists to a pharma company, so it no longer has to evaluate five fill finish partners and six packaging partners on its own. (02:46) Why early discussions matter, from the year of user and human factors studies after a device is chosen to a full and complete submission to the regulators. (04:03) What Ensera wants to hear from pharma companies at CPHI: referral opportunities, and the pain points the network is built to help avoid. Watch the full episode to hear how the Ensera Alliance Network plans to support patients and customer projects. Register your interest for CPHI Frankfurt 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-arto Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent/ Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent TikTok: https://www.tiktok.com/@artotalent Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@artotalent Darren Hieber LinkedIn: https://www.linkedin.com/in/darren-hieber-59517637/ Ruby Collier LinkedIn: https://www.linkedin.com/in/ruby-collier/ Timestamps: 00:00 Introduction 01:26 How the network helps pharma 02:31 Collaboration across the network 03:50 What Ensera wants to hear at CPHI 05:01 Closing thoughts #Newsbeat #ARTOTalent #CPHI #CPHIMilan #CombinationProducts #FillFinish #DrugDelivery #PharmaPackaging Hosted on Acast. See acast.com/privacy for more information.

    CPHI Milan 2026 Newsbeat: Ensera Launches The Ensera Alliance Network - Darren Hieber

  7. Oct 26

    CPHI Milan 2026 Newsbeat: AI's $30m Yield Boost In Pharma Manufacturing - Pep Gubau

    For Pep Gubau, AI is ready for pharma manufacturing, and the results are already measurable: one of Aizon's early adopters, a plasma derivatives manufacturer, raised its yield by 4% in three months, worth $30 million. This year CPHI gave AI a dedicated zone of its own. On Newsbeat, live at CPHI Milan 2026, Ruby Collier spoke to Pep Gubau, CEO and Founder of Aizon, about where AI is delivering results in pharma manufacturing. In this episode, Pep covers: (00:31) What a dedicated AI zone at CPHI means to a company that has focused on AI for pharma manufacturing for more than 12 years, and the interest now coming from manufacturers. (02:20) Why the manufacturing floor needs deterministic machine learning rather than large language models, and how digital capacity raises yield and avoids deviations. (04:32) Where language models are useful, where machine learning belongs in GMP, and why, for the first time in his 40 years in pharma, he sees regulators such as the FDA and EMA ahead of the industry. (07:23) Two results: a 4% yield increase worth $30 million in three months for a plasma derivatives manufacturer, and a CDMO that brought its deviation batches down to zero with predictive analytics. Watch the full episode to hear why Pep sees change management as the real work in adopting AI, and showing value as the way to win people over. Register your interest for CPHI Frankfurt 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-arto Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent/ Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent TikTok: https://www.tiktok.com/@artotalent Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@artotalent Pep Gubau LinkedIn: https://www.linkedin.com/in/jgubau/ Ruby Collier LinkedIn: https://www.linkedin.com/in/ruby-collier/ Timestamps: 00:00 Introduction 02:07 How AI is changing pharma manufacturing 04:19 Hype versus reality 07:09 Results so far and what comes next 10:27 Closing thoughts #Newsbeat #ARTOTalent #CPHI #CPHIMilan #AIinPharma #PharmaManufacturing #MachineLearning #GMP Hosted on Acast. See acast.com/privacy for more information.

    CPHI Milan 2026 Newsbeat: AI's $30m Yield Boost In Pharma Manufacturing - Pep Gubau

  8. Oct 23

    CPHI Milan 2026 Newsbeat: CinnaGen Receives Marketing Authorisation In Europe - Haleh Hamedifar

    CinnaGen is the first company from its region to receive a European marketing authorisation for a biosimilar. Present in more than 40 countries, CinnaGen is now coming to Europe for the first time. On Newsbeat, live at CPHI Milan 2026, Ruby Collier spoke to Haleh Hamedifar, Chairperson of CinnaGen, about the approval and the partners CinnaGen is looking for in Europe. In this episode, Haleh covers: (00:27) Why the European marketing authorisation, the first for a biosimilar from CinnaGen's region, is so meaningful for the company. (00:58) How an integrated model and in-house development let CinnaGen move faster and bring down costs, and why quality has to become part of a company's culture over years. (02:43) The foundations a company needs to compete in a highly regulated market: an integrated system from R&D to market access, people who understand the science and the regulations, and shareholders with a long-term view. (04:42) The partners CinnaGen is looking for at CPHI: reputable sales, marketing and market access partners in Europe, and co-development partners, for example on monoclonal antibodies. Watch the full episode to hear how CinnaGen, with 20 years of experience producing complex biopharmaceuticals, is preparing for Europe. Register your interest for 2027 here: https://www.cphi.com/europe/register-attend/?utm_source=partner&utm_medium=referral&utm_campaign=hln27cpw-cl-arto Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent/ Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent TikTok: https://www.tiktok.com/@artotalent Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@artotalent Haleh Hamedifar LinkedIn: https://www.linkedin.com/in/haleh-hamedifar-06516548/ Ruby Collier LinkedIn: https://www.linkedin.com/in/ruby-collier/ Timestamps: 00:00 Introduction 00:43 Lessons from the European approval 02:24 Foundations for the European market 04:25 The partners CinnaGen wants at CPHI 05:48 Closing thoughts #Newsbeat #ARTOTalent #CPHI #CPHIMilan #Biosimilars #Biopharma #MonoclonalAntibodies #MarketAccess Hosted on Acast. See acast.com/privacy for more information.

    CPHI Milan 2026 Newsbeat: CinnaGen Receives Marketing Authorisation In Europe - Haleh Hamedifar
See All (53)

About

97% of our listeners don't realise they aren't followed, please double check, thank you! Hosted by Thomas McMann, Making It In Manufacturing is ARTO's new in-person podcast series, spotlighting the leaders shaping the future of manufacturing, engineering and CDMOs in Life Sciences. Each episode dives into the careers, decisions, and defining moments of industry mainstays - revealing the stories and insights behind real-world impact within the life science manufacturing and CDMO space. If you're a leader in the space - or aspiring to be - this podcast is a must watch. The series is available on YouTube, Spotify, Apple Podcasts and all major platforms. Hosted on Acast. See acast.com/privacy for more information.

Information